Evidence map›Paper›PMID 39921899›Full record

ArticleJNCI cancer spectrum2025

Prostate cancer screening in the Middle East and North Africa: a cross-sectional study on current practices.

Ozlem Aynaci, Yetkin Tuac, Layth Mula-Hussain, Lubna Hammoudeh, Salameh Obeidat, Enas Abu Abeelh, Ahmed H Ibrahim, Sepideh Mohammadipour, Bader Alali, Ahmed Jdaini and 17 more

Abstract read
In one paragraph

Article in JNCI cancer spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Ozlem AynaciKaradeniz Technical University, Trabzon 61080, Türkiye.ORCID 0000-0002-1799-5521
Yetkin TuacDepartment of Statistics, Ankara University, Ankara 06100, Türkiye.ORCID 0000-0001-6590-3233
Layth Mula-HussainFaculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada.ORCID 0000-0003-0218-7270
Lubna HammoudehOregon Health and Science University, Portland, OR 97239, United States.
Salameh ObeidatOregon Health and Science University, Portland, OR 97239, United States.ORCID 0000-0002-2694-2253
Enas Abu AbeelhPrimary Health Care Corporation, Doha, Qatar.
Ahmed H IbrahimAin Shams University, Cairo 11566, Egypt.ORCID 0000-0002-9134-3492
Sepideh MohammadipourHacettepe University, Ankara 06100, Türkiye.
Bader AlaliJaber Al Ahmad Hospital, Kuwait, Kuwait.ORCID 0000-0002-3860-4040
Ahmed JdainiMohammed VI University Medical Center, Oujda 60050, Morocco.ORCID 0000-0002-4673-8479
Ali BarkiMohammed VI University Medical Center, Oujda 60050, Morocco.
Nesrine MejriAbderrahmen Mami Hospital, Ariana 2080, Tunisia.ORCID 0000-0001-7647-5027
Zeinab AlhaddadKing Hamad University Hospital, Al Sayh, Bahrain.
Nadeem PervezSheikh Shakhbout Medical City, Abu Dhabi 11001, UAE.ORCID 0000-0003-3821-4357
Hussain Al HussainKing Fahd Medical City, Riyadh 12231, Saudi Arabia.ORCID 0000-0001-7533-0088
Mohamad KadriAlBaironi Hospital, Damascus, Syria.
Mohamed A ElfagiehNational Cancer Institute, Misurata, Libya.
Adda BounedjarUniversity of Blida, Blida 09000, Algeria.
Moamin JunaidUniversity of Ninevah, Mosul 41002, Iraq.ORCID 0000-0002-0615-8840
Ahmed M BadheebHadhramout University, Mukalla, Yemen.ORCID 0000-0002-9753-5583
Ibrahim Abu GhidaBurjeel Medical City, Abu Dhabi, United Arab Emirates.
Shalini MoningiDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, United States.
Jonathan E LeemanDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, United States.
Peter F OrioDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, United States.
Paul L NguyenDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, United States.ORCID 0000-0003-4268-3973
Anthony V D'AmicoDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, United States.ORCID 0000-0002-4084-9944
Mutlay SayanDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, United States.ORCID 0000-0002-0101-0951

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer is a substantial health concern in the Middle East and North Africa region, with many cases diagnosed at advanced stages, a high mortality to incidence ratio, and low prostate cancer awareness. This study aimed to evaluate prostate cancer screening practices in the region to inform effective early detection and management strategies.

methodsA cross-sectional survey was conducted from July 1, 2023, to November 8, 2024, among physicians from 19 countries in the Middle East and North Africa region. The study used a validated questionnaire to assess prostate cancer screening practices, barriers, and educational needs.

resultsThe survey had a response rate of 96.8% and 1163 participants. Of these participants, 34.7% routinely performed prostate cancer screenings, with 61.1% using prostate-specific antigen tests. The primary barrier was lack of patient awareness (51.2%). In addition, 65.3% of participants had no formal training. To improve screening rates, participants suggested better patient education (63.5%), increased training for health-care professionals (41.9%), and improved access to screening equipment (38.9%).

conclusionThis study revealed that prostate cancer screening rates were low, with barriers including a lack of patient awareness and formal training among physicians. Addressing these issues through culturally tailored education programs may improve early detection rates and ultimately reduce the burden of prostate cancer in the Middle East and North Africa region.

Indexed as

Early Detection of CancerPractice Patterns, Physicians'Prostatic NeoplasmsAdultAfrica, NorthernAgedCross-Sectional StudiesHealth Knowledge, Attitudes, PracticeHumansMaleMass ScreeningMiddle AgedMiddle EastPatient Education as TopicProstate-Specific AntigenSurveys and QuestionnairesProstate-Specific Antigen

Identifiers

PMID39921899
PMCPMC11927531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.